Traphagen Investment Advisors LLC Decreases Stake in Pfizer Inc. (NYSE:PFE)

Traphagen Investment Advisors LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 8.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 30,380 shares of the biopharmaceutical company’s stock after selling 2,891 shares during the period. Traphagen Investment Advisors LLC’s holdings in Pfizer were worth $806,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Bourgeon Capital Management LLC increased its position in shares of Pfizer by 610.3% in the fourth quarter. Bourgeon Capital Management LLC now owns 418,658 shares of the biopharmaceutical company’s stock valued at $11,107,000 after acquiring an additional 359,721 shares during the period. Octavia Wealth Advisors LLC grew its stake in shares of Pfizer by 49.3% in the fourth quarter. Octavia Wealth Advisors LLC now owns 22,159 shares of the biopharmaceutical company’s stock worth $588,000 after purchasing an additional 7,319 shares during the last quarter. Fort Washington Investment Advisors Inc. OH increased its holdings in Pfizer by 1.4% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,629,388 shares of the biopharmaceutical company’s stock valued at $43,228,000 after purchasing an additional 22,562 shares during the period. JBGlobal.com LLC bought a new position in Pfizer during the 4th quarter valued at approximately $362,000. Finally, Chesley Taft & Associates LLC lifted its holdings in Pfizer by 2.6% in the 4th quarter. Chesley Taft & Associates LLC now owns 152,440 shares of the biopharmaceutical company’s stock worth $4,044,000 after buying an additional 3,833 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on PFE shares. Wolfe Research initiated coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. Citigroup assumed coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective for the company. Guggenheim cut their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. UBS Group decreased their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Finally, Sanford C. Bernstein began coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is currently owned by insiders.

Pfizer Price Performance

PFE opened at $26.63 on Wednesday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The stock has a 50-day moving average price of $26.08 and a 200-day moving average price of $27.98. The firm has a market cap of $150.89 billion, a PE ratio of 35.98, a P/E/G ratio of 0.63 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the prior year, the company posted ($0.17) earnings per share. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.46%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is currently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.